

## Special Issue

# Cystic Fibrosis and Rare Mutations: New Promising Approaches via Proteostase Modulators

### Message from the Guest Editor

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a cAMP-regulated chloride (Cl<sup>-</sup>) and bicarbonate (HCO<sub>3</sub><sup>-</sup>) channel expressed at the apical membrane of epithelial cells. The most common mutation—F508del—is present in 80% of individuals with CF worldwide. This Special Issue invites both reviews and original articles that shed light on the rational design and development of new PMs to be exploited in CF patients, including virtual screening applications and high-throughput screening (HTS) campaigns. Biological assays that lead to the discovery of novel hit compounds that can be further probed for different CFTR mutants are also included in the scope of the Special Issue. This Special Issue aims to summarize the state of the-art, and the latest findings published in the cystic fibrosis field, as well as to elucidate future directions.

### Guest Editor

Dr. Elena Cichero  
Department of Pharmacy, University of Genoa, Viale Benedetto XV,  
16132 Genoa, Italy

### Deadline for manuscript submissions

closed (16 February 2024)



## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/163329](https://mdpi.com/si/163329)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)